Drawing for EQUISEQ

USPTO serial 79191637

EQUISEQ

Reviewed by CopyMark Law Group

Reg. 5343156Status 404
Filing date
Status date
Registration date
Nov 28, 2017
Examiner
GALAN, MATTHEW
Law office
TMO LAW OFFICE 113

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EQUISEQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roberta S. Bren

Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.4000 Legato Road, Suite 310Fairfax, VA 22033UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical preparations and substances for the treatment of inflammation, arthritis and diseases of the central nervous system; ] veterinary * therapeutic * pharmaceutical preparations for treating laminitis, debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis inflammations, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), bone splints, joint sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; diagnostic preparations for veterinary use; drug delivery agents consisting of non-pharmaceutical nanostructure compounds that facilitate skin delivery of a wide range of pharmaceuticals for therapeutic effect; drug delivery agents consisting of non-pharmaceutical nanostructure chemical compounds that facilitate skin delivery of a wide range of pharmaceuticals for therapeutic effect; chemical reagents for veterinary purposes; diagnostic preparations for veterinary use; chemical reagents for veterinary purposes; anti-inflammatory drugs; pharmaceuticals for the treatment of hoof fungal infections; medicated preparations in the nature of creams, lotions, dissolvable films, ointments, topical solutions, dental lacquers, gels, and sprays for treating inflammation and pain; medicated preparations in the nature of creams, gels and lotions for use in the treatment of inflammatory diseases, disease of the mouth, teeth, skin, hair and ear, eczema, psoriasis and painSECTION 71 - CANCELLED—
010Medical devices for topical use in the treatment of pain; molecular filtering devices for veterinary use; veterinary devices for the treatment of laminitis and debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis inflammations, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), bone splints, joint sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; veterinary drug delivery devices for dosage regulation of non-pharmaceutical nanostructures that migrate through the skin and have a physical therapeutic effect at the point of complaint; veterinary drug delivery devices for dosage regulation of dispensed anti-inflammatory veterinary preparations in the nature of gels, lotions and creams; veterinary drug delivery devices for dosage regulation of dispensed veterinary preparations in the nature of skin surfactants, creams and powders, all of which deliver nanostructures through the skin; veterinary drug delivery devices for dosage regulation of pain relief therapy and prophylaxis preparations and substancesSECTION 71 - CANCELLED—
044Animal healthcare services * aimed at the treatment of bones, joints, skins and/or muscular diseases and diseases of the central nervous system for animals; * [ veterinary services; ] advisory services relating to the healthcare of animals; hiring of veterinary instruments, namely, rental of veterinary medical instruments; veterinary advisory services * regarding the treatment of bones, joints, skins and/or muscular diseases and diseases of the central nervous system for animals; * shoeing horses and maintaining horses' hooves; information services relating to the diagnostic, prophylactic and therapeutic properties of veterinary pharmaceuticals; information services relating to the veterinary pharmaceutical industry * aimed at the treatment of bones, joints, skins and/or muscular diseases and diseases of the central nervous system for animals, * namely, providing information relating to the diagnostic, prophylactic and therapeutic properties of veterinary pharmaceuticals; [ veterinary services including screening, diagnostic and testing services; veterinary specialty services providing advanced medical and diagnostic services for animals; ] providing online information in the field of animal healthcare *, namely, providing online information regarding the treatment of bones, joints, skins and/or muscular diseases and diseases of the central nervous system for animals; * animal grooming; animal breedingSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 12, 2026DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Feb 12, 2026DETHDEATH OF INTERNATIONAL REGISTRATION—
Nov 30, 2025DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Nov 30, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
May 16, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Apr 28, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 28, 2025INPCINVALIDATION PROCESSED—
Feb 14, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 14, 2024C71TCANCELLED SECTION 71—
Nov 28, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jan 3, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 9, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 4, 2019INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Apr 14, 2019INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 14, 2018COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Aug 14, 2018APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 10, 2018LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Jul 6, 2018LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Apr 27, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 9, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 9, 2018FIMPFINAL DISPOSITION PROCESSED—
Feb 28, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 28, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 12, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 12, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 23, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 8, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 8, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Aug 8, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 8, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 8, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 3, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 3, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 3, 2017ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 16, 2017GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Apr 16, 2017GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 16, 2017CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 21, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 20, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 20, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 13, 2016RFNTREFUSAL PROCESSED BY IB—
Sep 21, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 21, 2016RFRRREFUSAL PROCESSED BY MPU—
Sep 20, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 20, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 19, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2016DOCKASSIGNED TO EXAMINER—
Sep 16, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 15, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance